BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 20869873)

  • 21. Selectivity criterion for pyrazolo[3,4-b]pyrid[az]ine derivatives as GSK-3 inhibitors: CoMFA and molecular docking studies.
    Patel DS; Bharatam PV
    Eur J Med Chem; 2008 May; 43(5):949-57. PubMed ID: 17707953
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibitory mode of N-phenyl-4-pyrazolo[1,5-b] pyridazin-3-ylpyrimidin-2-amine series derivatives against GSK-3: molecular docking and 3D-QSAR analyses.
    Xiao J; Guo Z; Guo Y; Chu F; Sun P
    Protein Eng Des Sel; 2006 Feb; 19(2):47-54. PubMed ID: 16339768
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of potent pyrazolo[4,3-h]quinazoline-3-carboxamides as multi-cyclin-dependent kinase inhibitors.
    Traquandi G; Ciomei M; Ballinari D; Casale E; Colombo N; Croci V; Fiorentini F; Isacchi A; Longo A; Mercurio C; Panzeri A; Pastori W; Pevarello P; Volpi D; Roussel P; Vulpetti A; Brasca MG
    J Med Chem; 2010 Mar; 53(5):2171-87. PubMed ID: 20141146
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Three-dimensional quantitative structure-activity relationship studies on novel series of benzotriazine based compounds acting as Src inhibitors using CoMFA and CoMSIA.
    Gueto C; Ruiz JL; Torres JE; Méndez J; Vivas-Reyes R
    Bioorg Med Chem; 2008 Mar; 16(5):2439-47. PubMed ID: 18065233
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combined 3D-QSAR modeling and molecular docking study on quinoline derivatives as inhibitors of P-selectin.
    Zeng H; Cao R; Zhang H
    Chem Biol Drug Des; 2009 Dec; 74(6):596-610. PubMed ID: 19843078
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular Modeling and Design Studies of Purine Derivatives as Novel CDK2 Inhibitors.
    Zhang G; Ren Y
    Molecules; 2018 Nov; 23(11):. PubMed ID: 30423939
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 3D-QSAR studies of Checkpoint Kinase Weel inhibitors based on molecular docking, CoMFA and CoMSIA.
    Yi P; Fang X; Qiu M
    Eur J Med Chem; 2008 May; 43(5):925-38. PubMed ID: 17698256
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 3D-QSAR studies of JNK1 inhibitors utilizing various alignment methods.
    Madhavan T; Chung JY; Kothandan G; Gadhe CG; Cho SJ
    Chem Biol Drug Des; 2012 Jan; 79(1):53-67. PubMed ID: 21722320
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular docking and 3D QSAR studies on 1-amino-2-phenyl-4-(piperidin-1-yl)-butanes based on the structural modeling of human CCR5 receptor.
    Xu Y; Liu H; Niu C; Luo C; Luo X; Shen J; Chen K; Jiang H
    Bioorg Med Chem; 2004 Dec; 12(23):6193-208. PubMed ID: 15519163
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Potential choline kinase inhibitors: a molecular modeling study of bis-quinolinium compounds.
    Srivani P; Sastry GN
    J Mol Graph Model; 2009 Feb; 27(6):676-88. PubMed ID: 19147382
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular modeling studies to characterize N-phenylpyrimidin-2-amine selectivity for CDK2 and CDK4 through 3D-QSAR and molecular dynamics simulations.
    Chohan TA; Chen JJ; Qian HY; Pan YL; Chen JZ
    Mol Biosyst; 2016 Apr; 12(4):1250-68. PubMed ID: 26883408
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibitory mode of indole-2-carboxamide derivatives against HLGPa: molecular docking and 3D-QSAR analyses.
    Liu G; Zhang Z; Luo X; Shen J; Liu H; Shen X; Chen K; Jiang H
    Bioorg Med Chem; 2004 Aug; 12(15):4147-57. PubMed ID: 15246091
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 3D-QSAR and docking studies of aminopyridine carboxamide inhibitors of c-Jun N-terminal kinase-1.
    Yi P; Qiu M
    Eur J Med Chem; 2008 Mar; 43(3):604-13. PubMed ID: 17602798
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 3D-QSAR studies of boron-containing dipeptides as proteasome inhibitors with CoMFA and CoMSIA methods.
    Zhu YQ; Lei M; Lu AJ; Zhao X; Yin XJ; Gao QZ
    Eur J Med Chem; 2009 Apr; 44(4):1486-99. PubMed ID: 18771818
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Insights into the structural requirements of farnesyltransferase inhibitors as potential anti-tumor agents based on 3D-QSAR CoMFA and CoMSIA models.
    Puntambekar DS; Giridhar R; Yadav MR
    Eur J Med Chem; 2008 Jan; 43(1):142-54. PubMed ID: 17448576
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Understanding the structure-activity and structure-selectivity correlation of cyclic guanine derivatives as phosphodiesterase-5 inhibitors by molecular docking, CoMFA and CoMSIA analyses.
    Yang GF; Lu HT; Xiong Y; Zhan CG
    Bioorg Med Chem; 2006 Mar; 14(5):1462-73. PubMed ID: 16263288
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Modeling ligand-receptor interaction for some MHC class II HLA-DR4 peptide mimetic inhibitors using several molecular docking and 3D QSAR techniques.
    Wei HY; Tsai KC; Lin TH
    J Chem Inf Model; 2005; 45(5):1343-51. PubMed ID: 16180911
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 3D-QSAR and molecular docking studies of 1,3,5-triazene-2,4-diamine derivatives against r-RNA: novel bacterial translation inhibitors.
    Sekhar YN; Nayana MR; Sivakumari N; Ravikumar M; Mahmood SK
    J Mol Graph Model; 2008 Jun; 26(8):1338-52. PubMed ID: 18372201
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 3D-QSAR and molecular docking studies of selective agonists for the thyroid hormone receptor beta.
    Du J; Qin J; Liu H; Yao X
    J Mol Graph Model; 2008 Sep; 27(2):95-104. PubMed ID: 18436460
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 3D-QSAR and molecular docking studies on benzothiazole derivatives as Candida albicans N-myristoyltransferase inhibitors.
    Sheng C; Zhu J; Zhang W; Zhang M; Ji H; Song Y; Xu H; Yao J; Miao Z; Zhou Y; Zhu J; Lü J
    Eur J Med Chem; 2007 Apr; 42(4):477-86. PubMed ID: 17349719
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.